What's Happening?
LEO Pharma Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for ANZUPGO® (delgocitinib) cream. This cream is intended for the treatment
of moderate to severe chronic hand eczema (CHE) in pediatric patients aged 12 to 17 years. ANZUPGO is a topical, non-steroidal pan-Janus kinase (JAK) inhibitor, currently approved for adults in the U.S. who have not responded adequately to topical corticosteroids. The acceptance of this application marks a significant step towards addressing the unmet medical needs of pediatric patients with CHE, who currently lack approved treatment options. The application is supported by data from the DELTA TEEN trial, which demonstrated the efficacy and safety of ANZUPGO in this age group.
Why It's Important?
The FDA's acceptance of the sNDA for ANZUPGO cream is crucial as it addresses a significant gap in treatment options for pediatric patients with chronic hand eczema. This condition can severely impact the quality of life, causing symptoms like itching, pain, and skin blistering, which can interfere with daily activities. The lack of approved treatments for children highlights the importance of this development. If approved, ANZUPGO would be the first treatment specifically indicated for pediatric CHE, potentially improving the lives of many young patients. This development also underscores LEO Pharma's commitment to expanding its dermatological treatment offerings in the U.S. market.
What's Next?
Following the FDA's acceptance of the sNDA, the next steps involve a detailed review process by the agency. If the FDA approves the application, ANZUPGO could become available for pediatric use, providing a new treatment option for children suffering from CHE. LEO Pharma will likely continue to engage with the FDA throughout the review process and prepare for potential market introduction. Additionally, the company may focus on further research and development to expand the use of ANZUPGO in other regions and age groups, reinforcing its position in the dermatology market.
